October 6, 2012
Minnesota identifies meningitis case linked to injectable steroid product
A Minnesota woman in her forties has been diagnosed with meningitis after receiving injectable steroids from a compounding pharmacy in Massachusetts.
As of Friday evening, steroid products produced by the New England Compounding Center had been linked to 47 cases of fungal meningitis - and five death - in seven states, according to the U.S. Centers for Disease Control and Prevention (CDC).
The Minnesota patient was evaluated after experiencing possible symptoms of meningitis, including fever and headache. Evidence of meningitis was subsequently found in her spinal fluid. She has been hospitalized, and is being treated with antibiotic and antifungal drugs.
The only Minnesota health care providers known to have used the implicated drugs are Medical Advanced Pain Specialists (MAPS) in Edina, Fridley, Shakopee and Maple Grove, and the Minnesota Surgery Center (MSC) in Edina and Maple Grove. The Minnesota Department of Health (MDH) is continuing to work closely with MAPS and MSC to contact patients who were treated with steroids from the Massachusetts firm.
Approximately 950 Minnesota patients are now believed to have been treated with the implicated steroid products. As of Saturday morning, approximately 350 of the patients had been contacted by MDH or MAPS. Officials hope to finish contacting the rest by Sunday night.
The New England Compounding Center has been closed. All of its products have been recalled, or are currently being withheld from use. MDH officials are emphasizing that the fungal infections associated with the steroid products are different from the viral and bacterial forms of meningitis that may be more familiar to most Minnesotans. The fungal infections cannot be transmitted from person to person, so people who have not been treated with the implicated steroid products are not at risk.
Note: Current case numbers nationwide are available from CDC at: